AKT1 and type 2 diabetes mellitus: The targets for metformin were mainly enriched in FOXO, AMPK, insulin, and PI3K-Akt signaling pathways, whereas those for vildagliptin were enriched in insulin secretion, cAMP, and maturity onset diabetes of the young pathways (Figure S1).